According to Bristol-Myers Squibb’s (BMY) investor presentation, the company expects to create a leading oncology franchise across both the solid tumor and hematologic malignancy segments after completing the acquisition of Celgene (CELG). The company expects Opdivo, Yervoy, Revlimid, and Pomalyst to be the key growth drivers of its oncology portfolio in the future.
According to Bristol-Myers Squibb’s M&A conference transcript, Bristol-Myers Squibb has already managed to reach up to $7.5 billion of annualized revenues from the sale of its immuno-oncology products. The company has also secured more regulatory approvals in more than 17 indications in the US market and more than 400 approvals across the world for Opdivo.
According to the company’s investor presentation, Bristol-Myers Squibb expects its combination with Celgene to also create one of the leading immunology and inflammation franchises driven by Otezla and Orencia. Finally, according to the company’s investor presentation, the combined company is expected to be a top-ranking cardiovascular player led by Eliquis.
In addition to a robust commercial portfolio, the combined company is also expected to have a solid early as well as late-stage research pipeline. According to the company’s investor presentation, Bristol-Myers Squibb will be launching six new products in the next one to two years after the completion of the acquisition of Celgene. Additionally, the combined company will have ten phase 3 programs and multiple label expansion programs for commercialized products in its late-stage research pipeline.
According to the company’s investor presentation, Bristol-Myers Squibb also expects to create a robust early and mid-stage research pipeline with 21 immuno-oncology assets in solid tumor indications, ten oncology assets in the hematology indication, nine assets in cardiovascular and fibrosis indications, and ten immunology and inflammation assets.
In the next article, we’ll discuss growth drivers for Bristol-Myers Squibb’s oncology business in greater detail.